Real-life studies in allergen immunotherapy

被引:12
|
作者
Passalacqua, Giovanni [1 ]
Bagnasco, Diego [1 ]
机构
[1] Univ Genoa, Allergy & Resp Dis, IRCCS Policlin San Martino, Lgo R Benzi 10, I-16133 Genoa, Italy
关键词
allergen immunotherapy; efficacy; real life; real world; safety; RANDOMIZED CONTROLLED-TRIALS; ADVERSE SYSTEMIC REACTIONS; SUBLINGUAL IMMUNOTHERAPY; EUROPEAN SURVEY; ASTHMA; RHINITIS; SAFETY; MANAGEMENT; EFFICACY; EASSI;
D O I
10.1097/ACI.0000000000000757
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Purpose of review Real-life (or real-world) studies can provide information that cannot be derived from randomized controlled trials. This approach is currently becoming of relevance for many treatments. In recent years, the real-life method has been applied also to allergen immunotherapy, providing new insights on it. We reviewed herein the available literature on the argument. Recent findings Several prospective and retrospective studies on allergen immunotherapy in the real-world setting have been published, mostly in the last 5 years. Most of them focused on adverse events, compliance, and the long term/preventive effects, and evidenced an overall favorable profile for different products and different allergens. Real life study provided novel information and evidenced those aspects of immunotherapy that worth a more detailed approach, without the strict limitations usually imposed by controlled randomized trials.
引用
收藏
页码:361 / 367
页数:7
相关论文
共 50 条
  • [1] The growing importance of real-life studies in allergen immunotherapy
    Incorvaia, C.
    Barberi, S.
    Pastorello, E.
    Ciprandi, G.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 51 (03) : 115 - 121
  • [2] Real-life safety of allergen immunotherapy in children and adolescents
    Wahn, Ulrich
    Valovirta, Erkka
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2017, 28 (01) : 71 - 71
  • [3] Real-life approach to allergen immunotherapy for respiratory diseases in childhood
    Scala, Guglielmo
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 45 (06) : 187 - 192
  • [4] Real-life safety study with a mixed allergen immunotherapy in polyallergic patients
    Florido, F.
    Merida, C.
    Lara, M. A.
    Rojas, M. J.
    Rodriguez, E.
    Callero, A.
    Rodriguez, B.
    Baquero, D.
    Moreno, A.
    Moral, A.
    Alcantara, M.
    Mayorgas, R.
    Rodriguez, A.
    Jimenez, M. M.
    Garcia, J.
    Matas, M.
    Buendia, I
    ALLERGY, 2021, 76 : 49 - 50
  • [5] Adherence to Subcutaneous Allergen Immunotherapy in Southeast Turkey: A Real-Life Study
    Tat, Tugba S.
    MEDICAL SCIENCE MONITOR, 2018, 24 : 8977 - 8983
  • [6] Efficacy of allergen immunotherapy for allergic rhinoconjunctivitis assessed by conjunctival allergen provocationa real-life study
    Vasconcelos, M. J.
    Mesquita, A. M.
    Rama, T.
    Moco, Coutinho R.
    Miranda, J.
    Placido, J. L.
    Silva, D.
    ALLERGY, 2020, 75 : 51 - 52
  • [7] Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy
    Kiel, Menno A.
    Roder, Esther
    van Wijk, Roy Gerth
    Al, Maiwenn J.
    Hop, Wim C. J.
    Rutten-van Molken, Maureen P. M. H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (02) : 353 - +
  • [8] Use of quality of life (QOL) scores to assess allergen immunotherapy outcomes in a real-life setting
    Rahman, T.
    Gandhi, B.
    Morrison, C.
    Msonthi, A.
    Ali, F. R.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2016, 46 (12): : 1638 - 1638
  • [9] Real-life data on inactivated COVID-19 vaccination in patients with subcutaneous allergen immunotherapy
    Xu, Yingyang
    Guan, Kai
    CLINICAL AND TRANSLATIONAL ALLERGY, 2022, 12 (01)
  • [10] European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment
    Calderon, M. A.
    Vidal, C.
    Rodriguez del Rio, P.
    Just, J.
    Pfaar, O.
    Tabar, A. I.
    Sanchez-Machin, I.
    Bubel, P.
    Borja, J.
    Eberle, P.
    Reiber, R.
    Bouvier, M.
    Lepelliez, A.
    Klimek, L.
    Demoly, P.
    ALLERGY, 2017, 72 (03) : 462 - 472